請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24731
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭彥彬(Mark Yen-Ping Kuo) | |
dc.contributor.author | Cheng-Chang Yeh | en |
dc.contributor.author | 葉正昌 | zh_TW |
dc.date.accessioned | 2021-06-08T05:38:52Z | - |
dc.date.copyright | 2011-10-03 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-25 | |
dc.identifier.citation | 1.Notani PN. Epidemiology and prevention of head and neck cancer: a global view. In: Saranath D, editor. Contemporary issues in oral cancer. New Delhi: Oxford University Press; 2000, p. 1–29.
2.Ries LAG, Kosary CL, Hankey BF, Miller BA, Clogg L, Edwards BK, editors. SEER cancer statistics review, 1973-1996. Bethesda: National Cancer Institute; 1999. 3.Clayman GL, Lippman SM, Laramore GE, Hong WK. Head and neck cancer. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum R, editors. Cancer medicine. Philadelphia: Williams and Wilkins; 1996, p. 1645–1709. 4.Neville BW, Day TA. Oral cancer and precancerous lesions [review]. CA Cancer J Clin 2002;52:195–215. 5.Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002;24:165–80. 6.Kim R, Emi M, Tanabe K, Uchida Y, Arihiro K. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment [review]. Eur J Surg Oncol 2006;32:269–77. 7.Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease [review]. Pharmacol Rev 2005;57: 187–215. 8.Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155–62. 9.Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med 1999;5: 157–63. 10.Fukuda M, Hamao A, Tanaka A, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity. Oncol Rep 2003;10: 1113–9. 11.Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev 2006;6: 38–51. 12.Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009;45:610–4. 13.Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001; 115:287–97. 14.Henderson C , Mizzau M, Paroni G, Maestro R, Schneider C , Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003;278:12579–89. 15.Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77–84. 16.Sonnemann J, Hartwig M, Plath A, Saravana Kumar K, Muller C, Beck JF. Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett 2006;2322:148–60. 17.Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007;6:2967–75. 18.Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101:4055–62. 19.Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001;98: 10833–8. 20.Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 2007; 30:1181–8. 21.Jia LQ, Osada M, Ishioka C, et al. Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog 1997; 19:243–53. 22.Ohnishi K, Ota I, Takahashi A, Yane K, Matsumoto H, Ohnishi T. Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck. Apoptosis 2002;7:367–72. 23.Lee J, Huang MS, Yang IC, et al. Essential roles of caspases and their upstream regulators in rotenone-induced apoptosis. Biochem Biophys Res Commun 2008;371:33–8. 24.Kok SH, Cheng SJ, Hong CY, et al. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett 2005;217:43–52. 25.Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosisinducing ligand and express death receptor 4 and death receptor 5. Cancer Res 2001;61:2704–12. 26.Jang YJ, Park KS, Chung HY, Kim HI. Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities. Cancer Lett 2003;194: 107–17. 27.Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Cancer Res 1999;59:734–41. 28.Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2Linduced apoptosis of human acute leukemia cells. Blood 2000;96:3900–6. 29.Sonnemann J, Gange J, Kumar KS, Muller C, Bader P, Beck JF. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines [review]. Invest New Drugs 2005;23:99–109. 30.Singh TR, Shankar S, Srivastava RK. HDACi nhibitors enhance the apoptosis- inducing potential of TRAIL in breast carcinoma. Oncogene 2005;24:4609–23. 31.Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 2007;29: 272–84. 32.Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/ DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000;19:1735–43. 33.Johnston JB, Kabore AF, Strutinsky J, et al. Role of the TRAIL/APO2- L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003;22:8356–69. 34.Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ. Exp C ell Res 2001;262:154–69. 35.De-Yuan Sha, Suberoylanilide Hydroxamic Aicd (SAHA) induced growth arrest and apoptosis in oral cancer cells. Master Thesis 2005 Ashkenazi, A., Holland, P., and Eckhardt, S.G. (2008). Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26, 3621-3630. Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., Blackie, C., Chang, L., McMurtrey, A.E., Hebert, A., et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104, 155-162. Bommareddy, A., Hahm, E.R., Xiao, D., Powolny, A.A., Fisher, A.L., Jiang, Y., and Singh, S.V. (2009). Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res 69, 3704-3712. Brech, A., Ahlquist, T., Lothe, R.A., and Stenmark, H. (2009). Autophagy in tumour suppression and promotion. Mol Oncol 3, 366-375. Budihardjo, I., Oliver, H., Lutter, M., Luo, X., and Wang, X. (1999). Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15, 269-290. Chen, Y.R., and Tan, T.H. (2000). The c-Jun N-terminal kinase pathway and apoptotic signaling (review). Int J Oncol 16, 651-662. Chen, Y.R., Wang, W., Kong, A.N., and Tan, T.H. (1998). Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem 273, 1769-1775. Chen, Y.R., Wang, X., Templeton, D., Davis, R.J., and Tan, T.H. (1996). The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271, 31929-31936. Davis, R.J. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252. Ehrhardt, H., Fulda, S., Schmid, I., Hiscott, J., Debatin, K.M., and Jeremias, I. (2003). TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22, 3842-3852. Elrod, H.A., and Sun, S.Y. (2008). Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 7, 163-173. Fulda, S., Jeremias, I., and Debatin, K.M. (2004). Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 23, 7611-7620. Galluzzi, L., Blomgren, K., and Kroemer, G. (2009). Mitochondrial membrane permeabilization in neuronal injury. Nat Rev Neurosci 10, 481-494. Galluzzi, L., Vicencio, J.M., Kepp, O., Tasdemir, E., Maiuri, M.C., and Kroemer, G. (2008). To die or not to die: that is the autophagic question. Curr Mol Med 8, 78-91. Green, D.R. (2000). Apoptotic pathways: paper wraps stone blunts scissors. Cell 102, 1-4. Green, D.R., and Reed, J.C. (1998). Mitochondria and apoptosis. Science 281, 1309-1312. Guan, B., Yue, P., Clayman, G.L., and Sun, S.Y. (2001). Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 188, 98-105. Guan, B., Yue, P., Lotan, R., and Sun, S.Y. (2002). Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene 21, 3121-3129. Guo, Z., Smith, T.J., Wang, E., Sadrieh, N., Ma, Q., Thomas, P.E., and Yang, C.S. (1992). Effects of phenethyl isothiocyanate, a carcinogenesis inhibitor, on xenobiotic-metabolizing enzymes and nitrosamine metabolism in rats. Carcinogenesis 13, 2205-2210. Hecht, S.S. (1995). Chemoprevention by isothiocyanates. J Cell Biochem Suppl 22, 195-209. Hecht, S.S., Chung, F.L., Richie, J.P., Jr., Akerkar, S.A., Borukhova, A., Skowronski, L., and Carmella, S.G. (1995). Effects of watercress consumption on metabolism of a tobacco-specific lung carcinogen in smokers. Cancer Epidemiol Biomarkers Prev 4, 877-884. Hengartner, M.O. (2000). The biochemistry of apoptosis. Nature 407, 770-776. Hu, R., Kim, B.R., Chen, C., Hebbar, V., and Kong, A.N. (2003). The roles of JNK and apoptotic signaling pathways in PEITC-mediated responses in human HT-29 colon adenocarcinoma cells. Carcinogenesis 24, 1361-1367. Ip, Y.T., and Davis, R.J. (1998). Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. Curr Opin Cell Biol 10, 205-219. Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., and Yoshimori, T. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19, 5720-5728. Law, B.Y., Wang, M., Ma, D.L., Al-Mousa, F., Michelangeli, F., Cheng, S.H., Ng, M.H., To, K.F., Mok, A.Y., Ko, R.Y., et al. (2010). Alisol B, a novel inhibitor of the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis. Mol Cancer Ther 9, 718-730. LeBlanc, H.N., and Ashkenazi, A. (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10, 66-75. Levine, B., and Kroemer, G. (2008). Autophagy in the pathogenesis of disease. Cell 132, 27-42. Mahalingam, D., Szegezdi, E., Keane, M., de Jong, S., and Samali, A. (2009). TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 35, 280-288. Maiuri, M.C., Zalckvar, E., Kimchi, A., and Kroemer, G. (2007). Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8, 741-752. Massano, J., Regateiro, F.S., Januario, G., and Ferreira, A. (2006). Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102, 67-76. Meley, D., Bauvy, C., Houben-Weerts, J.H., Dubbelhuis, P.F., Helmond, M.T., Codogno, P., and Meijer, A.J. (2006). AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem 281, 34870-34879. Miyoshi, N., Uchida, K., Osawa, T., and Nakamura, Y. (2004). Benzyl isothiocyanate modifies expression of the G2/M arrest-related genes. Biofactors 21, 23-26. Mizushima, N., Yamamoto, A., Matsui, M., Yoshimori, T., and Ohsumi, Y. (2004). In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 15, 1101-1111. Nagane, M., Huang, H.J., and Cavenee, W.K. (2001). The potential of TRAIL for cancer chemotherapy. Apoptosis 6, 191-197. Nagaraj, N.S., Vigneswaran, N., and Zacharias, W. (2006). Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells. J Cancer Res Clin Oncol 132, 171-183. Nakamura, Y., and Miyoshi, N. (2006). Cell death induction by isothiocyanates and their underlying molecular mechanisms. Biofactors 26, 123-134. Park, H.U., Suy, S., Danner, M., Dailey, V., Zhang, Y., Li, H., Hyduke, D.R., Collins, B.T., Gagnon, G., Kallakury, B., et al. (2009). AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 8, 733-741. Pullar, J.M., Thomson, S.J., King, M.J., Turnbull, C.I., Midwinter, R.G., and Hampton, M.B. (2004). The chemopreventive agent phenethyl isothiocyanate sensitizes cells to Fas-mediated apoptosis. Carcinogenesis 25, 765-772. Ravi, R., Bedi, G.C., Engstrom, L.W., Zeng, Q., Mookerjee, B., Gelinas, C., Fuchs, E.J., and Bedi, A. (2001). Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 3, 409-416. Scully, C., and Bagan, J.V. (2008). Recent advances in Oral Oncology 2007: imaging, treatment and treatment outcomes. Oral Oncol 44, 211-215. Shankar, S., Chen, Q., Ganapathy, S., Singh, K.P., and Srivastava, R.K. (2008). Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Mol Cancer Ther 7, 2328-2338. Shaw, M.M., Gurr, W.K., McCrimmon, R.J., Schorderet, D.F., and Sherwin, R.S. (2007). 5'AMP-activated protein kinase alpha deficiency enhances stress-induced apoptosis in BHK and PC12 cells. J Cell Mol Med 11, 286-298. Sheikh, M.S., Burns, T.F., Huang, Y., Wu, G.S., Amundson, S., Brooks, K.S., Fornace, A.J., Jr., and el-Deiry, W.S. (1998). p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58, 1593-1598. Sheridan, J.P., Marsters, S.A., Pitti, R.M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C.L., Baker, K., Wood, W.I., et al. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821. Shi, Y. (2002). Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9, 459-470. Singh, S.V., Srivastava, S.K., Choi, S., Lew, K.L., Antosiewicz, J., Xiao, D., Zeng, Y., Watkins, S.C., Johnson, C.S., Trump, D.L., et al. (2005). Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem 280, 19911-19924. Srivastava, S.K., Xiao, D., Lew, K.L., Hershberger, P., Kokkinakis, D.M., Johnson, C.S., Trump, D.L., and Singh, S.V. (2003). Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis 24, 1665-1670. Takimoto, R., and El-Deiry, W.S. (2000). Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19, 1735-1743. Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P.J., Achanta, G., Arlinghaus, R.B., Liu, J., et al. (2006). Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10, 241-252. Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M.P., Deen, K.C., McLaughlin, M.M., Srinivasula, S.M., Livi, G.P., Marshall, L.A., et al. (2000). Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275, 23319-23325. Tsantoulis, P.K., Kastrinakis, N.G., Tourvas, A.D., Laskaris, G., and Gorgoulis, V.G. (2007). Advances in the biology of oral cancer. Oral Oncol 43, 523-534. Verheij, M., Bose, R., Lin, X.H., Yao, B., Jarvis, W.D., Grant, S., Birrer, M.J., Szabo, E., Zon, L.I., Kyriakis, J.M., et al. (1996). Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380, 75-79. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5, 157-163. Wang, C.W., and Klionsky, D.J. (2003). The molecular mechanism of autophagy. Mol Med 9, 65-76. Wang, L.G., Beklemisheva, A., Liu, X.M., Ferrari, A.C., Feng, J., and Chiao, J.W. (2007). Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog 46, 24-31. Wang, S. (2008). The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27, 6207-6215. Waterhouse, N.J., Goldstein, J.C., von Ahsen, O., Schuler, M., Newmeyer, D.D., and Green, D.R. (2001). Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. J Cell Biol 153, 319-328. Wei, Y., Pattingre, S., Sinha, S., Bassik, M., and Levine, B. (2008). JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 30, 678-688. Wolf, B.B., and Green, D.R. (1999). Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 274, 20049-20052. Wu, S.J., Ng, L.T., and Lin, C.C. (2005). Effects of antioxidants and caspase-3 inhibitor on the phenylethyl isothiocyanate-induced apoptotic signaling pathways in human PLC/PRF/5 cells. Eur J Pharmacol 518, 96-106. Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J., and Greenberg, M.E. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331. Xiao, D., Lew, K.L., Zeng, Y., Xiao, H., Marynowski, S.W., Dhir, R., and Singh, S.V. (2006). Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 27, 2223-2234. Xu, Z.X., Liang, J., Haridas, V., Gaikwad, A., Connolly, F.P., Mills, G.B., and Gutterman, J.U. (2007). A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase. Cell Death Differ 14, 1948-1957. Yan, J., Yang, H., Wang, G., Sun, L., Zhou, Y., Guo, Y., Xi, Z., and Jiang, X. (2010). Autophagy augmented by troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling. Autophagy 6, 67-73. Yang CC, Study on the potential usage of phenethyl isothiocynate for the treatment of oral cancer. Master Thesis 2005 Yeh, C.C., Deng, Y.T., Sha, D.Y., Hsiao, M., and Kuo, M.Y. (2009). Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol Cancer Ther 8, 2718-2725. Younes, A., and Kadin, M.E. (2003). Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 21, 3526-3534. Yu, R., Mandlekar, S., Harvey, K.J., Ucker, D.S., and Kong, A.N. (1998). Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease activity. Cancer Res 58, 402-408. Zanke, B.W., Rubie, E.A., Winnett, E., Chan, J., Randall, S., Parsons, M., Boudreau, K., McInnis, M., Yan, M., Templeton, D.J., et al. (1996). Mammalian mitogen-activated protein kinase pathways are regulated through formation of specific kinase-activator complexes. J Biol Chem 271, 29876-29881. Zhang, Y. (2004). Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutat Res 555, 173-190. Zhang, Y., and Talalay, P. (1994). Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res 54, 1976s-1981s. Zhang, Y., Tang, L., and Gonzalez, V. (2003). Selected isothiocyanates rapidly induce growth inhibition of cancer cells. Mol Cancer Ther 2, 1045-1052. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167-1174. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24731 | - |
dc.description.abstract | Suberoylanilide hydroxamic acid (SAHA),屬於 HDAC2 的專屬抑制劑,近年來已經被證實在多種腫瘤細胞中,可誘發腫瘤細胞的自殺性凋亡,因此 SAHA 被認為是很有潛力的抗腫瘤藥物。 SAHA 結合放射性治療、cisplatin 和腫瘤壞死因子相關的誘導凋亡配體 (TRAIL),在多種腫瘤的治療結果中,有很好的效果。此這篇研究,我們證明了 SAHA可以誘發口腔癌細胞進行自殺性凋亡,在西方墨點的實驗結果中,我們發現了 SAHA 增加了 Fas、Fas ligand、DR4 和 DR5 的蛋白表現量,同時也活化了 caspase-8 和 caspase-9 的活性。而 SAHA 所誘發的細胞凋亡可以被 caspase-8 的抑制劑 Z-IETD-FMK 完全抑制,而 caspase-9的抑制劑 Z-LEHD-FMK 則可減少一部分 SAHA 所誘發的細胞凋亡。人類 DR5/Fc 重組抗體 可以有效地抑制 SAHA 所誘發的細胞凋亡,但Fas/Fc 或DR4/Fc 卻無法抑制 SAHA 所誘發的細胞凋亡,這些結果顯示出 SAHA 所誘發的細胞凋亡,主要是透過活化 DR5/TRAIL 的死亡路徑。 此外,針對 SAHA 的次毒性濃度測試顯示,SAHA 可以引起對 TRAIL 有耐受度的兩株人類口腔癌細胞-SAS 和 Ca9-22 對外加的 TRAIL ,重新引起細胞自殺性凋亡,且這個凋亡反應與 p53 基因沒有相關聯。因此,結合 SAHA 和 TRAIL 同時在口腔癌的治療上,在未來可能是一個相當具潛力的新治療方式。
除了SAHA 外,近年來發現,在水田芥植物中所發現的自然化合物,PEITC也屬於 HDAC2 的抑制劑,可以誘發細胞周期的停止和細胞凋亡。 先前的研究顯示出 PEITC 具有顯著預防及治療口腔鱗狀細胞癌的功效。 本研究我們將探討 PEITC 誘發口腔鱗狀細胞癌細胞凋亡的效能與機轉,為了釐清 PEITC 所誘發的細胞凋亡機轉,我們的研究包含了: 死亡接受器、caspases、粒線體的胞色素的釋放和 MAPK 相關的訊號傳遞路徑。 根據西方墨點的實驗結果,當細胞在 PEITC 處理之後會使得 DR4 和 DR5 的蛋白質表現量上升,此外 PEITC 也活化了 caspase-8 和 caspase -9 當加入 caspase-8 和 caspase -9 的專一抑制劑,同時也抑制了 PEITC 所誘發的細胞凋亡。當加入JNK、ERK 和 p38 個別的專一抑制劑時,只有 JNK 的抑制劑-SP600125 可以減少 PEITC 所引發的細胞凋亡,這個結果顯示出 JNK 的活性在細胞凋亡過程中扮演著重要的角色甚至和 DR4 與 DR5 的蛋白質表現量上升並使細胞對 TRAIL 更加敏感有關。 PEITC 會誘發 ROS 的產生並使 JNK 活化,使得細胞進入凋亡的程序,當加入 ROS 的清除試劑 NAC 便抑制了 PEITC 所誘發的細胞凋亡。這個結果顯示 PEITC 所誘發 ROS 的產生,是造成細胞凋亡的主因。此外 PEITC 也會在 SAS 和Ca9-22 細胞中誘發 autophagy 透過活化 AMPK 的訊息路徑, 且 PEITC 所誘發的 autophagy 扮演著促使細胞死亡的角色。 在這篇研究中我們發現 PEITC 可引發ROS 的產生且活化 JNK 的活性,並造成 DR4 和 DR5 的 mRNA 和蛋白質表現量的上升,最後造成細胞凋亡。而且 PEITC 也在 SAS 和 Ca9-22 細胞中引起促進細胞死亡的 autophagy。 | zh_TW |
dc.description.abstract | Suberoylanilide hydroxamic acid has been shown to selectively induce tumor apoptosis in cell cultures and animal models in several types of cancers and is about as a promising new class of chemotherapeutic agents. In addition, SAHA showed synergistic anticancer activity with radiation, cisplatin, and tumor necrosis factor–related apoptosis–inducing ligand (TRAIL) in some cancers. Here, we report SAHA also induced apoptosis in human oral cancer cells. Western blotting showed SAHA increased Fas, Fas ligand, DR4, and DR5 protein expression and activated caspase-8 and caspase-9. The apoptosis was almost completely inhibited by caspase- 8 inhibitor Z-IETD-FMK and attenuated by caspase-9 inhibitor Z-LEHD-FMK. Human recombinant DR5/Fc chimera protein but not Fas/Fc or DR4/Fc significantly inhibited apoptosis induced by SAHA. These results suggest that SAHA induces apoptosis mainly through activation of DR5/TRAIL death pathway. Furthermore, subtoxic concentrations of SAHA sensitize to TRAIL resistant human oral cancer cells, SAS and Ca9-22, to exogenous recombinant TRAIL-induced apoptosis in a p53-independent manner. Combined treatment of SAHA and TRAIL may be used as a new promising therapy for oral cancer.
Recently, it has been found that phenethyl isothiocyanate (PEITC), a naturally occurring isothiocyanate especially abundant in watercress, could induce cell cycle arrest and apoptotic cell death. Previous studies showed that PEITC have significant chemopreventive and possibly chemotherapeutic effects in OSCC cells. Here we investigated the pro-apoptotic effect of PEITC and the mechanisms of apoptosis induced by PEITC in human OSCC cell lines, SAS and Ca9-22. To understand apoptotic mechanisms induced by PEITC, we studied the role of death receptors, caspases, mitochondria-cytochrome c release, and mitogen-activated protein kinase (MAPK) signaling pathways involved in PEITC-induced apoptosis. The western blot data shows that DR-5 and DR-4 were up-regulated after PEITC treatment in SAS and Ca9-22 cells. Both the caspase-8 and -9 activities were stimulated by PEITC and the apoptosis was almost completely inhibited either by caspase-8 inhibitor Z-IETD-FMK or caspase-9 inhibitor Z-LEHD-FMK. PEITC could induce apoptosis in SAS and ca9-22 cells in a time dependent manner via the mitochondria caspase cascade. Three MAPKs, JNK (c-Jun N-terminal kinase), ERK (extracellular signal-regulated protein kinase) and p38 kinase, were evaluated after PEITC treatment in SAS and Ca9-22 cells. JNK activation was obviously induced by PEITC. The activation of JNK is critical for the initiation of the apoptotic processes and sensitive to TRAIL-induced cell death by up-regulating DR5 and DR4 via generation of reactive oxygen species (ROS), leading to rapid induction of TRAIL-mediated signaling and cell death. Importantly, the SP600125 compound, an anthrapyrazolone inhibitor of JNK, but not the ERK and p38 inhibitors, attenuated both DR4 and DR5 up-regulated and suppressed apoptosis caused by PEITC. Here we had shown that apoptosis induction by PEITC in human oral cancer cells is associated with ROS-dependent activation of JNK. PEITC -mediated ROS production, JNK activation, and/or apoptosis in human oral cancer cells were significantly attenuated by pretreatment with NAC. The mechanism of PEITC plays an important role in the killing of cancerous cells and offers a potential therapeutic strategy for its anticancer action in vivo. This study demonstrated that PEITC not only induces JNK-dependent DR4 and DR5 upregulation dependent of ROS generation but also induces autophagy via the AMPK pathway and the PEITC-induced autophagy plays the role of promoting cell death in SAS and Ca9-22 cells. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:38:52Z (GMT). No. of bitstreams: 1 ntu-100-D96422001-1.pdf: 12742126 bytes, checksum: cb204a5bfa1079e1a818aa13933a100c (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員審定書 …………………………………………………I
誌謝………………………………………………………………II Contents…………………………………………………………III 中文摘要…………………………………………………………IV Abbreviations……………………………………………………VI Chapter 1: Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression………………………………………1 Abstract……………………………………………………………2 Introduction………………………………………………………3 Materials and Methods……………………………………………7 Results………………………………………………………………10 Result figures ……………………………………………………15 Discussion…………………………………………………………21 References…………………………………………………………26 Chapter 2: Molecular mechanisms for PEITC sensitization of death receptor mediated apoptosis in oral cancer………30 Abstract …………………………………………………………31 Introduction……………………………………………………33 Materials and Methods ………………………………………42 Results …………………………………………………………46 Result figures ………………………………………………56 Discussion………………………………………………………70 References………………………………………………………78 Publication ……………………………………………………85 Appendix ………………………………………………………86 | |
dc.language.iso | en | |
dc.title | SAHA及PEITC在死亡受器引發口腔癌細胞凋亡訊息機轉之研究 | zh_TW |
dc.title | Molecular mechanisms for SAHA and PEITC sensitization of death receptor mediated apoptosis in oral cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 張國威,蕭宏昇,張正琪,周涵怡 | |
dc.subject.keyword | 細胞凋亡,死亡接受器,口腔癌, | zh_TW |
dc.subject.keyword | SAHA,PEITC,TRAIL,DR5,ROS,Apoptosis,Autophagy, | en |
dc.relation.page | 108 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2011-07-26 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 12.44 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。